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Introduction
FK506 (tacrolimus) is a powerful immunosuppressive drug
that plays an important therapeutic role after liver, heart, lung,
and kidney transplantation. It was initially expected to be less
nephrotoxic than cyclosporine. However, nephrotoxicity in
the form of renal tubular acidosis (RTA), secondary to the use
of FK506 in liver or kidney transplant patients, has recently
been reported.1–5 We report our experience of hyperkalaemic
RTA secondary to FK506 administration in a paediatric case
after living donor liver transplantation.
Case report
A 6-month-old girl was treated with FK506 after undergoing
living donor liver transplantation for fulminant hepatitis. She
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was weaned from artificial ventilation on postoperative day 5,
and her serum total bilirubin and transaminase levels gradu-
ally decreased with good graft liver function (Figure). The
FK506 trough concentration was maintained at around
15 ng/mL. On postoperative day 17, the patient demonstrated
hyperkalaemia and metabolic acidosis in spite of a normal
serum creatinine concentration and normal blood urea
nitrogen. The laboratory data at that time are shown in the
Table. Distal RTA due to impaired secretion of potassium was
suspected based on the low urinary potassium concentrations
and hyperkalaemia. She was diagnosed to have hyperkalaemic
distal RTA with aldosterone deficiency (type IV). Therefore,
intravenous sodium bicarbonate and furosemide, and
intrarectal calcium polystyrenesulfonate were administered
to correct the acidosis and to promote potassium secretion.
Thereafter, the FK506 concentration in whole blood gradually
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decreased to 10 ng/mL, and oral administration of furosemide
was started. The hyperkalaemia and metabolic acidosis fol-
lowing RTA improved without oral administration of bicarbo-
nate (Figure).
Discussion
Two types of nephrotoxicity induced by FK506 have so far
been reported. One is reduction of the glomerular filtration
rate caused by renal vasoconstriction,6 and the other is tubu-
lar dysfunction, which most frequently causes RTA.1–5 Both
proximal and distal tubular dysfunction have been reported,
and this patient was diagnosed to have hyperkalaemic distal
RTA with aldosterone deficiency (type IV) because of
hyperkalaemia, as well as high urinary pH and a low aldoste-
rone concentration. The mechanism of distal RTA induced by
FK506 has not yet been elucidated. However, two possible
mechanisms have been described. FK506 may depress the
juxtaglomerular system or may have a direct effect on distal
tubular function. Juxtaglomerular hyperplasia and cell trans-
formation have been reported in patients treated with
FK506.7 These morphological changes are associated with a
decrease in the activity of the renin-aldosterone system. In
addition, FK506 administration has been reported to result
in a decrease in the rate of hydrogen ion secretion by the
collecting tubules.1,2 In our case, both mechanisms may have
caused the symptoms since both aldosterone deficiency and
systemic acidosis occurred.
The first priority in treating RTA following FK506 admin-
istration is appropriately treating both the hyperkalaemia and
systemic acidosis. Sodium bicarbonate, furosemide, or cal-
cium polystyrenesulfonate should be administered to correct
acidosis and promote potassium secretion. Thereafter, the
FK506 concentration should be decreased if possible. In our
case, intravenous sodium bicarbonate and furosemide, and
intrarectal calcium polystyrenesulfonate were initially
administered. Thereafter, the FK506 concentration was gradu-
ally reduced to 10 ng/mL, when oral administration of furo-
semide was started. Both the hyperkalaemia and metabolic
acidosis following RTA improved, and the patient no longer
needed to take oral bicarbonate regularly. However, a case has
been reported in which treatment with oral bicarbonate did
not improve the systemic acidosis associated with systemic
oedema and hypernatraemia.1 In such cases, reducing the
dosage of FK506 should be considered.
Table. Laboratory data
Blood gas analysis
pH 7.389
pCO2 26.1 mmHg
HCO3- 15.4 mmol/L
BE –7.9 mmol/L
Renal function
Serum Cr 21.2 µmol/L
BUN 6.8 mmol/L
Electrolytes
Na 132 mmol/L
K 6.5 mmol/L
Cl 104 mmol/L
Endocrine
Aldosterone 0.086 nmol/L
Plasma renin activity 0.31 nmol/L/hr
Urine
pH 6.5
uNa 71 mmol/L
uK 14.3 mmol/L
uCl 90 mmol/L
pCO2 = carbon dioxide partial pressure; BE = base excess;
Cr = creatinine; BUN = blood urea nitrogen.
Figure. Clinical course after transplantation and postoperative
changes in serum total bilirubin (T-Bil), aspartate aminotransferase
(AST) and bicarbonate (HCO3-), and FK506 levels in whole blood.
BE = base excess.
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The onset of RTA due to FK506 administration varies.
A reported case of a 10-month-old infant showed RTA
on postoperative day 21.1 Our case also presented with
RTA within 1 month of transplantation. In contrast, a
23-month-old patient demonstrated RTA 15 months after
undergoing liver transplantation.3 Therefore, the occurrence
of RTA should be carefully considered whenever FK506 is
used.
RTA is an important complication to consider when-
ever FK506 is administered after organ transplantation.
It is normally reversible with appropriate treatment in
mild cases. Even if RTA is not a fatal complication, un-
treated RTA might impair growth after transplantation.
Therefore, close attention should always be paid to the
possibility of RTA whenever FK506 is used after any organ
transplantation. The treatment for acidosis and hyperka-
laemia should be started as soon as RTA is diagnosed,
and thereafter, the dosage of FK506 should be reduced if
possible.
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